GSK
GlaxoSmithKline PLC
50.50$
+0.3%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +63.6% | -67.1% | -6.5% | +93.5% | +8.1% | -50.8% | +83.1% | +44.4% | -32.7% | -44.0% | +122.2% | – | |
| – | +152.4% | -52.4% | -8.2% | +48.8% | -56.7% | +99.8% | +40.8% | -14.1% | -21.3% | -40.8% | -51.6% | – | |
| – | +0.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1,010.7% | -121.6% | – | – | – | -121.0% | – | – | – | -178.2% | – | – | |
| – | +18.2% | -46.5% | +40.6% | +90.5% | +34.8% | -60.5% | +41.3% | -32.3% | +30.8% | -20.9% | -25.7% | – | |
| – | – | -187.2% | – | -194.9% | +53.1% | +2.2% | -45.4% | +244.0% | +9.9% | -38.0% | -39.9% | – | |
| – | +18.9% | +6.8% | -9.5% | -6.1% | +0.0% | +0.0% | +7.2% | +38.0% | -30.6% | +2.3% | +13.3% | – | |
| – | -644.4% | – | – | – | +0.0% | -1,335.0% | +127.1% | -20.1% | +204.0% | -76.1% | -5.4% | – | |
| – | – | – | – | – | – | +686.1% | -145.6% | -90.2% | – | +115.7% | -153.5% | – | |
| – | +130.6% | -69.1% | +26.3% | -21.7% | -32.1% | – | -376.5% | -28.0% | – | -66.4% | -799.9% | – | |
| – | – | – | – | -48.8% | +151.7% | +126.1% | -209.3% | – | – | -152.1% | – | – | |
| – | +76.7% | -71.1% | -23.4% | +95.5% | -9.0% | -41.6% | +109.9% | +77.7% | -43.2% | -52.7% | +216.1% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.